about
Chemical generation of bispecific antibodies.Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors.Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinomaCombined anticancer effects of sphingosine kinase inhibitors and sorafenib.Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer.Metastasis from renal cell carcinoma to the thyroid 12 years after nephrectomy.Characterization of the metabolism of benzaldehyde dimethane sulfonate (NSC 281612, DMS612).Down-regulation of PKCζ in renal cell carcinoma and its clinicopathological implications.MicroRNA target site polymorphisms in the VHL-HIF1α pathway predict renal cell carcinoma risk.Formation of active products of benzaldehyde dimethane sulfonate (NSC 281612, DMS612) in human blood and plasma and their activity against renal cell carcinoma lines.Vascularity of primary and metastatic renal cell carcinoma specimens.Pazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale"Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study.Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice.Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma.Elucidation of the molecular mechanisms underlying adverse reactions associated with a kinase inhibitor using systems toxicology.Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis.Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis.Pretreatment differentiation of renal cell carcinoma subtypes by CT: the influence of different tumor enhancement measurement approaches.Aqueous Extracts of Toona sinensis Leaves Inhibit Renal Carcinoma Cell Growth and Migration Through JAK2/stat3, Akt, MEK/ERK, and mTOR/HIF-2α Pathways.Risk of fatigue in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative meta-analysis.
P2860
Q34450000-F07C0A4A-E772-4992-96D9-FA57986E6322Q34572309-AF5D07AB-5837-4D56-BC24-2616FAF96151Q34658963-5F1F7410-EE1D-4F6E-881F-366ED5368456Q34949678-D22901EE-EA38-4F13-9A97-99E9191A9C59Q35166954-87932CD8-3D90-4B31-BA40-0FF97ABEB6E0Q35201216-914C3BA2-6B09-42E4-82C4-38A1BF67FB1EQ35984176-F846D4B1-E811-47DA-8B12-0A5BB9CADB44Q36034954-77E62392-1961-4FE7-8531-5009E0F5C148Q36179757-C74951C5-08D5-43DE-806F-AEB1D814825DQ36508219-B236FB0E-D728-4A60-A591-5AD1EFEC2712Q36578610-CB8877C6-A472-4C69-B985-94DB908AB02DQ37218304-129CB5CB-CF62-4764-9FC6-3AAC73583E00Q37290050-47E1367C-5209-4540-89F5-463DA88C8556Q37333224-71FB50E2-F2FA-49FF-9BAA-0B0FB41AB53DQ38642100-E587796D-6627-4992-8BD6-E9E1EFBF11FAQ41057002-377A01F7-31CE-4480-98B4-CA73F31BF5E4Q42603046-342326C5-B0C2-42C0-8974-75023F2384FFQ47136435-7859D778-0930-41F2-9113-B03DA25B69F3Q53084394-AAEB23F1-A4EF-4689-9160-B2B888B74BE4Q53114366-1A66530E-4672-4FDA-917F-2EA7BF4AA931Q53809725-CED7290B-1583-4930-A88B-5CBF63A1BE7E
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
New treatment approaches in renal cell carcinoma.
@en
New treatment approaches in renal cell carcinoma.
@nl
type
label
New treatment approaches in renal cell carcinoma.
@en
New treatment approaches in renal cell carcinoma.
@nl
prefLabel
New treatment approaches in renal cell carcinoma.
@en
New treatment approaches in renal cell carcinoma.
@nl
P2093
P1433
P1476
New treatment approaches in renal cell carcinoma.
@en
P2093
Carmela Pisano
Francesco Fiore
Francesco Perri
Gaetano Facchini
Luigi Marra
Michele Caraglia
Pasquale Aprea
Rosario Vincenzo Iaffaioli
Sandro Pignata
Stefano Striano
P304
P356
10.1097/CAD.0B013E32833123D4
P577
2009-11-01T00:00:00Z